Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor

Abstract No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic anti‐cachexia therapy and was unresponsive to anabolic doses of diverse androgens, including the selective androgen receptor modulato...

Full description

Saved in:
Bibliographic Details
Main Authors: Sophia G Liva, Yu‐Chou Tseng, Anees M Dauki, Michael G Sovic, Trang Vu, Sally E Henderson, Yi‐Chiu Kuo, Jason A Benedict, Xiaoli Zhang, Bryan C Remaily, Samuel K Kulp, Moray Campbell, Tanios Bekaii‐Saab, Mitchell A Phelps, Ching‐Shih Chen, Christopher C Coss
Format: Article
Language:English
Published: Springer Nature 2020-01-01
Series:EMBO Molecular Medicine
Subjects:
androgen
cachexia
HDAC inhibitor
selective androgen receptor modulator
STAT3
Online Access:https://doi.org/10.15252/emmm.201809910
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.201809910

Similar Items